65,437 trials
Abortion in First Trimester
Primary: Completion of Medication Abortion — 9 Participants
Chronic Hand Eczema
Primary: Number of Participants With IGA-CHE TS at Week 16 — 64; 16 Participants — p=0.006
Diabetes · Hypoglycaemia
Primary: Proportion of Participants With Captured Hypoglycaemia — 3 Participants
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.131147; NA months
Asthma in Children
Primary: Number of Subjects With a Significant Change in D. Pteronyssinus Levels at End of Study Evaluation — 0; 0 Participants
Obesity
Primary: Energy Expenditure (Oxygen Consumption) — 20.2; 22.8 ml/kg/min
Lower Limb Amputation Below Knee (Injury) · Lower Limb Amputation Above Knee (Injury) · Lower Limb Amputation Knee
Primary: Patient-perceived Mobility (PLUS-M)™ — 57.2; 56.9; 58.3; 57.6 units on a scale — p=0.286
Idiopathic Scoliosis
Primary: Incidence of Treatment-Emergent Adverse Events — 11; 7; 20; 0 Participants
Rehabilitation of Speech and Language Disorders · Speech Disorders · Speech, Alaryngeal
Primary: Pitch Recognition Accuracy — 7.70 Percent agreement to reference pitch
Hypoxia
Primary: Accuracy of Sensor Oxygen Saturation by Arms Calculation — 2.0 percentage of SpO2
Healthy Participants
Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for Bosutinib — 591.3; 591.7; 479.4 nanogram*hour per milliliter (ng*hr/mL)
Influenza, Human · COVID-19
Primary: Number of Participants With All Cause Hospitalization Visits: 18-64 Years Old — 1838; 705; 1837; 12715 Participants
Keratosis, Actinic
Primary: Change From Baseline in Domain Scores Using the Patient Reported Outcome Skindex-16 Instrument at Week 8 — 22.30; -14.26; 38.17; -24.88 score on a scale
Dentin Sensitivity
Primary: Mean Schiff Sensitivity Score (Average of the Two Selected Test Teeth) at Baseline (Day 0) — 2.43; 2.44; 2.44; 2.34 score on a scale
Advanced Breast Cancer · Metastatic Breast Cancer
Primary: Number of Participants According to Real-World Tumor Response — 72; 310; 499; 223 Participants